After identifying a promising molecule in our animal models, our main priority is to initiate a clinical trial to validate its effect in humans. Depending of the prevalence of the disease, we can initiate a very small (n-of-1) clinical trial or recruit patients more broadly.
Modelis’ has established partnerships with renowned clinicians with an extensive expertise in clinical trial design and development. If we confirm the therapeutic effect of the molecule, we establish a legal strategy to protect our discovery so we can approach larger biotech or pharmaceutical companies to sell them the rights to commercialize the treatment.
Our patient partners are involved all along this process and are a driving force in the clinical development. Our patient partners own part of the intellectual property of their treatment, which is why, they are also rewarded financially in the event of a commercial deal.
